Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC
Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC
Not yet recruiting · NCT06501664 · Registry updated 2024-07-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal cancer, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Not yet recruiting | Phase 3 | 2024-07-15 | NCT06501664 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Rui-hua Xu, MD, PhD | 3 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||